{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:15:56Z","timestamp":1792808156354,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106945","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:40:41Z","timestamp":1775756441000},"page":"106945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-5523","authenticated-orcid":false,"given":"J.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.-C.","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Casalnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-4726","authenticated-orcid":false,"given":"P.","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":false,"given":"L.A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Okera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-6556","authenticated-orcid":false,"given":"F.","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Magallanes-Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Karadurmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bahadur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3580-117X","authenticated-orcid":false,"given":"R.M.","family":"Speck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2697-0438","authenticated-orcid":false,"given":"J.","family":"Macey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-0794","authenticated-orcid":false,"given":"H.","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4429-6675","authenticated-orcid":false,"given":"S.","family":"Fairhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2068-5951","authenticated-orcid":false,"given":"J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-1254","authenticated-orcid":false,"given":"K.L.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2026.106945_bib1","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-18-2782","article-title":"Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database","volume":"25","author":"Hwang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106945_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106945_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100629","article-title":"Health-related quality of life in breast cancer patients treated with CDK4\/6 inhibitors: a systematic review","volume":"7","author":"Di Lauro","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106945_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106945_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106945_bib6","series-title":"Fulvestrant","year":"2021"},{"key":"10.1016\/j.esmoop.2026.106945_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103729","article-title":"Oral SERDs alone or in combination with CDK 4\/6 inhibitors in breast cancer: current perspectives and clinical trials","volume":"75","author":"Apostolidou","year":"2024","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106945_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12885-023-11722-4","article-title":"The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on \u2265 1 line of endocrine therapy: systematic review and meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.esmoop.2026.106945_bib9","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","article-title":"ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials","volume":"26","author":"Turner","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106945_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/0008-5472.CAN-24-2608","article-title":"Imlunestrant is an oral, brain-penetrant selective estrogen receptor degrader with potent antitumor activity in ESR1 wild-type and mutant breast cancer","volume":"85","author":"Bhagwat","year":"2025","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106945_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101265","article-title":"41P Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model","volume":"8","author":"VandeKopple","year":"2023","journal-title":"ESMO Open"},{"issue":"Suppl 13","key":"10.1016\/j.esmoop.2026.106945_bib12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1538-7445.AM2021-1236","article-title":"Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)","volume":"81","author":"Bhagwat","year":"2021","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106945_bib13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106945_bib14","series-title":"INLURIYO (imlunestrant) tablets HIGHLIGHTS OF PRESCRIBING INFORMATION","year":"2025"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106945_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","article-title":"The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making","volume":"24","author":"Bellino","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.esmoop.2026.106945_bib17","series-title":"Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies","year":"2016"},{"key":"10.1016\/j.esmoop.2026.106945_bib18","series-title":"Core patient-reported outcomes in cancer clinical trials guidance for industry","year":"2024"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106945_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2022.09.1949","article-title":"PCR14 A literature review of methodology used in in-trial interview studies in clinical development","volume":"25","author":"Alladin","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2026.106945_bib20","article-title":"Patient-focused drug development: methods to identify what is important to patients","year":"2022","journal-title":"Guidance for industry, Food and Drug Administration staff, and other stakeholders"},{"key":"10.1016\/j.esmoop.2026.106945_bib21","series-title":"EORTC QLQ-C30 (version 3)","year":"1995"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106945_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106945_bib24","series-title":"PRO-CTCAE","year":"2023"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106945_bib25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","article-title":"Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development","volume":"21","author":"Turner-Bowker","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2026.106945_bib26","article-title":"Patient-focused drug development: collecting comprehensive and representative input","year":"2020","journal-title":"Guidance for industry, Food and Drug Administration staff, and other stakeholders"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106945_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2023.09.2212","article-title":"MSR154 Qualitative content analysis for concept elicitation (CACE) in clinical outcome assessment development","volume":"26","author":"Carmichael","year":"2023","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106945_bib28","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106945_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13058-020-1246-5","article-title":"ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis","volume":"22","author":"Zundelevich","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106945_bib30","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol"},{"issue":"46","key":"10.1016\/j.esmoop.2026.106945_bib31","doi-asserted-by":"crossref","first-page":"74448","DOI":"10.18632\/oncotarget.12950","article-title":"Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor","volume":"7","author":"Clatot","year":"2016","journal-title":"Oncotarget"},{"issue":"Suppl 12","key":"10.1016\/j.esmoop.2026.106945_bib32","volume":"31","author":"Jhaveri","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106945_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2026.106945_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/PROM.S256567","article-title":"Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE\u00ae to provide two distinct and complementary perspectives","volume":"13","author":"Minasian","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106945_bib35","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","article-title":"Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy","volume":"25","author":"Kaufman","year":"2020","journal-title":"Oncologist"},{"issue":"Suppl 4","key":"10.1016\/j.esmoop.2026.106945_bib36","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106945_bib37","first-page":"32","article-title":"Large-volume IM injections: a review of best practices","volume":"4","author":"Hopkins","year":"2013","journal-title":"Oncol Nurse Advis"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106945_bib38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40271-024-00679-6","article-title":"Differences in preferences for drug therapy between patients with metastatic versus early-stage breast cancer: a systematic literature review","volume":"17","author":"Brandstetter","year":"2024","journal-title":"Patient"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106945_bib39","article-title":"Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer","volume":"28","author":"Ciruelos","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.esmoop.2026.106945_bib40","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.2147\/PPA.S432821","article-title":"Understanding patient preferences regarding the important determinants of breast cancer treatment: a narrative scoping review","volume":"17","author":"Yeo","year":"2023","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106945_bib41","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(22)00021-3","article-title":"Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials","volume":"23","author":"Fiero","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106945_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106945_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough? An experiment with data saturation and variability","volume":"18","author":"Guest","year":"2006","journal-title":"Field Methods"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106945_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","article-title":"Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report","volume":"12","author":"Coons","year":"2009","journal-title":"Value Health"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:32:46Z","timestamp":1776699166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008872"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106945","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106945"}}